Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review by Mark T. Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H. Poulsen, Karina Meijer, Mindy Simpson, Maria Elisa Mancuso

Get full text

Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial by Doris V. Quon, Jiaan-Der Wang, Michael Wang, Dominic Pepperell, Young-Shil Park, Gili Kenet, Johnny Mahlangu, Teh-Liane Khoo, Tara M. Robinson, Konstantia-Maria Chavele, Steven W. Pipe

Get full text

Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention by Nadine G. Andersson, Marloes de Kovel, Giancarlo Castaman, Roseline d’Oiron, Gili Kenet, Christoph Konigs, Christoph Male, Beatrice Nolan, Martin Olivieri, Fernando Pinto, Sigridur Sigurgisladottir, Ester Zapotocka, Kathelijn Fischer

Get full text

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial by Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington, Doris V. Quon, Adam Giermasz, Maria Fernanda López Fernández, Gili Kenet, Gillian Lowe, Nigel S. Key, Carolyn M. Millar, Steven W. Pipe, Bella Madan, Sheng-Chieh Chou, Robert Klamroth, Jane Mason, Hervé Chambost, Flora Peyvandi, Elaine Majerus, Dominic Pepperell, Christine Rivat, Hua Yu, Tara M. Robinson, Margareth C. Ozelo

Get full text